Medadvisor Ltd
ASX:MDR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.2
0.57
|
Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Medadvisor Ltd
Cost of Revenue
Medadvisor Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Medadvisor Ltd
ASX:MDR
|
Cost of Revenue
-AU$47.9m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-116%
|
CAGR 10-Years
N/A
|
||
Mach7 Technologies Ltd
ASX:M7T
|
Cost of Revenue
-AU$1.4m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
||
4DMedical Ltd
ASX:4DX
|
Cost of Revenue
-AU$236.7k
|
CAGR 3-Years
-37%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
||
CogState Ltd
ASX:CGS
|
Cost of Revenue
-$19.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-13%
|
||
Pro Medicus Ltd
ASX:PME
|
Cost of Revenue
-AU$301k
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
0%
|
||
Medibio Ltd
ASX:MEB
|
Cost of Revenue
-AU$160
|
CAGR 3-Years
91%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
Medadvisor Ltd
Glance View
MedAdvisor Ltd. engages in the provision of mobile and web software platform for prescription medication use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2011-05-26. The firm is engaged in the development and delivering software for personal medication management. The Company’s products include MedAdvisor App, PlusOne pharmacy platform. MedAdvisor App and its supporting software platform provides individuals and minders to manage all aspects of prescription medication use. Its cloud-based medication records and data connects pharmacies and other HCPs. The firm provides pharmaceutical health program..
See Also
What is Medadvisor Ltd's Cost of Revenue?
Cost of Revenue
-47.9m
AUD
Based on the financial report for Jun 30, 2024, Medadvisor Ltd's Cost of Revenue amounts to -47.9m AUD.
What is Medadvisor Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-116%
Over the last year, the Cost of Revenue growth was -24%. The average annual Cost of Revenue growth rates for Medadvisor Ltd have been -40% over the past three years , -116% over the past five years .